演題抄録

パネルディスカッション

開催概要
開催回
第56回・2018年・横浜
 

悪性胸膜中皮腫に対する新規免疫賦活・細胞内核酸受容体標的治療薬の開発

演題番号 : PD22-2

[筆頭演者]
演者)佐倉 千萬:1,2 
[共同演者]
金田 安史:3、玄山 宗到:4、栗林 康造:5、新谷 康:1、安宅 信二:6、小河原 光正:7、森 雅秀:8、竹内 幸康:8、熊谷 融:9、平島 智徳:10、木島 貴志:5、熊ノ郷 淳:11、中野 孝司:12、奥村 明之進:8

1:大阪大学・呼吸器外科、2:大阪大学・未来医療開発部、3:大阪大学・遺伝子治療学、4:大阪急性期・総合医療センター・呼吸器内科、5:兵庫医科大学・呼吸器内科、6:近畿中央胸部疾患センター・腫瘍内科、7:大阪医療センター・呼吸器内科、8:刀根山病院、9:大阪国際がんセンター・呼吸器内科、10:大阪はびきの医療センター・呼吸器内科、11:大阪大学・呼吸器・免疫内科、12:大手前病院・呼吸器内科

 

Hemagglutinating virus of Japan envelope (HVJ-E) is manufactured from Sendai virus (HVJ). HVJ-E is no replication ability, and no pathogen against human. HVJ-E possesses the various antitumor activities. HVJ-E acts on many steps of the cancer immunity cycle, because it enhances antitumor immunities such as activation of DC, induction of NK cells and CTL, suppression of regulatory T cells, and induces the immunogenic cell death through the RIG-I/MAVS pathway targeted by intratumoral administration of HVJ-E. We believe that HVJ-E is a novel antitumor agent that activates antitumor immune system and induces the tumor cell death. We confirmed that the therapeutic effectiveness of HVJ-E alone and combined with CDDP and Pemetrexed in human malignant pleural mesothelioma (MPM) bearing mice. We therefore performed the P-I dose escalation safety/tolerability and preliminary efficacy study of HVJ-E in patients suffering from chemotherapy-resistant MPM. We administrated HVJ-E to the patients 4 times per 2 weeks, and then washed out the drug from the body for 2 weeks. This cycle was repeated 2 times. Three patients as a low-dose group, and three patients as a high-dose group were enrolled. There was no discontinuation of the administration due to the severe adverse events. Neither serious adverse events (SAE) nor DLT were observed during the observation period. The local relapse of mesothelioma at the injection site was not observed. The efficacy as a secondary endpoint was evaluated with modified RECIST. DCR of low dose level cohort was 0%, because of PD, meanwhile, high dose level cohort indicated 100%. It was suggested the administration of HVJ-E was safe treatment, and useful for disease control of advanced MPM. We think it is reasonable that HVJ-E is used with chemotherapeutic agents or immune checkpoint inhibitor, because HVJ-E acts on many steps of the cancer immunity cycle. Now we are doing the P-II clinical trial for naive MPM with HVJ-E and standard chemotherapy.

前へ戻る